Funding
Respiratory infections biotech gets up everyone’s nose with $34 million Series B
Melbourne biotech ENA Respiratory has raised $34 million (US$22.4m) in a Series B funding round to support the development of its virus-agnostic nasal spray, INNA-051, designed to boost the body’s natural defences against respiratory infections. The raise was led by existing investors Brandon Capital and Uniseed, with participation from Stoic Venture Capital, the Gates Foundation… Read more »
